Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA119
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group report for this appraisal was prepared by the Centre for Health Economics, University of York (Walker S, Palmer S) and the NHS Northern and Yorkshire Regional Drug and Therapeutics Centre (Erhorn S, Brent S, Dyker A et al.), August 2006. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.

The following company provided a submission for this appraisal:

  • Schering Health Care Limited

The following organisations are consultees or commentators in this appraisal. They were invited to comment on the ACD and supporting evidence. Consultees are also invited to appeal against the final appraisal determination.

Professional or specialist, and patient or carer groups:

  • British Committee for Standards in Haematology

  • Cancer Networks Pharmacists Forum

  • Cancer Research UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Radiologists

  • Cancerbackup

  • CHILDREN with LEUKAEMIA

  • Chronic Lymphocytic Leukaemia Support Association

  • Leukaemia CARE

Other consultee organisations:

  • Department of Health

  • Welsh Assembly Government

Commentator organisations (without the right of appeal):

  • British National Formulary

  • NHS Quality Improvement Scotland

  • Janssen-Cilag Ltd

  • Roche Products Ltd

  • Liverpool Review and Implementation Group, University of Liverpool

  • National Coordinating Centre for Health Technology Assessment

  • National Collaborating Centre for Cancer

The following individuals were selected from clinical specialist and patient advocate nominations from the professional or specialist, and patient or carer groups. They gave their expert personal view on fludarabine by providing written and oral evidence to the Committee. They were also invited to comment on the appraisal consultation document (ACD).

  • Professor Terry Hamblin, Professor of Immunohaematology, nominated by the Leukaemia Research Fund as a clinical specialist

  • Dr Andrew Pettitt, Reader and Consultant Haematologist, nominated by the British Committee for Standards in Haematology as a clinical specialist

  • Jane Barnard, patient member, nominated by the Chronic Lymphocytic Leukemia Support Association as a patient expert

  • Dr Howard Pearce, chairman of and nominated by the Chronic Lymphocytic Leukemia Support Association as a patient expert

ISBN: 978-1-4731-7066-7